---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-155830"
form_type: "8-K"
ticker: "INO"
cik: "0001055726"
company_name: "INOVIO PHARMACEUTICALS, INC."
filed_at: "2025-07-07T23:59:59+00:00"
generated_at: "2026-05-18T09:14:35.515355+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Inovio prices $25M public offering of common stock and warrants

## Summary
- Gross proceeds of $25M from 14,285,715 shares and accompanying Series A/B warrants at $1.75/unit.
- Net proceeds expected ~$22.5M after underwriting discounts and expenses; closing on July 7, 2025.
- Underwriters have 30-day option for up to 2,142,857 additional shares and warrants.
- Series A warrants expire 12 months from issuance or 30 days after FDA acceptance of BLA for INO-3107.
- Series B warrants expire 5 years; Piper Sandler sole book-runner, Oppenheimer passive bookrunner.

## SEC filing metadata
- accession: 0001193125-25-155830
- form_type: 8-K
- ticker: INO
- cik: 0001055726
- company_name: INOVIO PHARMACEUTICALS, INC.
- filed_at: 2025-07-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1055726/000119312525155830/0001193125-25-155830-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1055726/000119312525155830/d15686d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-155830
- JSON: https://secwatch.observer/filing/0001193125-25-155830.json
- Plain text: https://secwatch.observer/filing/0001193125-25-155830.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.